Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
Venetoclax is a Bcl-2 homology domain 3 (BH3) mimetic currently approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) that has proven to be highly effective in reinstating apoptosis in leukemic cells through the highly selective inhibition of the anti-apop...
Saved in:
Main Authors: | Laura Giuseppina Di Pasqua (Author), Murwan Mahmoud Abdallah (Author), Fausto Feletti (Author), Mariapia Vairetti (Author), Andrea Ferrigno (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Changes in Glutathione Content in Liver Diseases: An Update
by: Mariapia Vairetti, et al.
Published: (2021) -
Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats
by: Giuseppina Palladini, et al.
Published: (2022) -
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure
by: James Griffin, et al.
Published: (2023) -
Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival
by: Hind A. Alkhatabi, et al.
Published: (2022) -
On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
by: Nina Žigart, et al.
Published: (2020)